Semaglutide vs Phentermine: Which Is Better for Weight Loss in

If you’ve been researching weight loss medication, you’ve probably come across both semaglutide and phentermine. They’re two of the most prescribed weight loss drugs in the US — but they’re fundamentally different in how they work, how long they can be used, and what the evidence says about results. Here’s the full comparison.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a weekly injection that mimics a gut hormone to suppress appetite, slow gastric emptying, and improve metabolic signalling. It’s available as Ozempic (approved for type 2 diabetes), Wegovy (approved for chronic weight management at 2.4 mg), and compounded semaglutide through telehealth providers.

It was developed by Novo Nordisk and has been extensively studied in large-scale randomised controlled trials, with weight loss outcomes that have genuinely changed what’s considered possible in obesity medicine.

What Is Phentermine?

Phentermine is a stimulant-class appetite suppressant — a Schedule IV controlled substance that’s been around since the 1950s. It works by stimulating your central nervous system to release norepinephrine, which suppresses hunger signals and slightly boosts metabolic rate.

It’s typically prescribed for short-term use (up to 12 weeks) and is sometimes combined with topiramate in a formulation called Qsymia for longer-term use. It comes as a daily oral tablet or capsule, which makes it simpler to take than a weekly injection.

Head-to-Head: Efficacy Comparison

This is where the gap becomes stark. Clinical data on semaglutide (specifically Wegovy at 2.4 mg) shows average weight loss of 14–17% of body weight over 68 weeks in the STEP trials. For someone weighing 250 lbs, that’s 35–42 lbs.

Phentermine monotherapy trials show average weight loss of around 3–5% of body weight over 12 weeks. Phentermine/topiramate (Qsymia) does better — up to 10–11% over a year — but that combination carries its own side effect profile including cognitive impairment risks from topiramate.

The key caveat: phentermine results are typically lost when you stop taking it. Weight regain is rapid and nearly universal. Semaglutide results also largely reverse upon stopping, but the treatment window is designed to be longer-term, and the metabolic benefits during treatment are more substantial.

Duration of Treatment

Phentermine: FDA-approved for short-term use only — typically 3 months maximum. Long-term prescribing is technically off-label and many physicians won’t do it. This is because phentermine carries addiction potential and cardiovascular risk with prolonged use.

Semaglutide: Designed for chronic weight management — the STEP trials ran up to 68 weeks, and many patients continue indefinitely. The ADA and obesity medicine guidelines support long-term use, especially in patients with metabolic comorbidities.

If you need a long-term solution (which most people dealing with obesity do), semaglutide is the clearer choice. Phentermine is really only suited to a short-term kickstart.

Side Effect Profiles

Semaglutide side effects are predominantly GI: nausea, vomiting, diarrhoea, constipation. These are typically worst in the first 4–8 weeks and improve significantly as your body adjusts. Serious but rare risks include pancreatitis and a theoretical (mainly seen in rodents) thyroid tumour risk.

Phentermine side effects include elevated heart rate, increased blood pressure, insomnia, dry mouth, anxiety, and irritability — classic stimulant effects. It’s contraindicated in people with heart disease, hyperthyroidism, glaucoma, or a history of drug abuse. The cardiovascular risk profile means it requires more careful screening than semaglutide.

From a cardiovascular safety standpoint, semaglutide is the winner — large trials actually show it reduces cardiovascular events in high-risk patients, while phentermine can raise heart rate and blood pressure.

Cost Comparison

Phentermine: Extremely affordable — as cheap as $10–30/month with a generic prescription. Insurance usually covers it.

Brand semaglutide (Wegovy): Expensive without insurance — around $1,300–$1,500/month retail. Covered by some insurance plans for obesity with comorbidities.

Compounded semaglutide: The middle ground — typically $200–$450/month through telehealth providers, no insurance needed, clinically equivalent to branded.

If budget is the primary concern, phentermine wins on cost — but you need to weigh that against its limitations. Compounded semaglutide has brought the cost of GLP-1 therapy within reach for most budgets.

Which One Should You Choose?

The answer depends on your situation. Here’s a simple framework:

• Choose phentermine if: You want a cheap, short-term appetite suppressant and you have no cardiovascular risk factors or contraindications. You accept that results won’t last after stopping.
• Choose semaglutide if: You want significant, sustained weight loss with strong clinical backing, a better cardiovascular safety profile, and a medication designed for long-term use. You’re willing to manage GI side effects initially and pay more (or use compounded semaglutide to manage costs).
• Consider both if: Some physicians combine phentermine short-term with semaglutide to accelerate early results while the semaglutide builds up. This is off-label but practised in some weight management clinics.

For most people serious about long-term weight management, semaglutide is the more evidence-based choice. Phentermine’s era as the go-to weight loss drug is effectively over — GLP-1 therapies have set a new clinical standard.

Frequently Asked Questions

Affiliate disclosure: This article contains sponsored links. We may earn a commission if you click through and make a purchase. See our full disclosure.